17149-35-8 Usage
Uses
Used in Pharmaceutical Research:
2-Amino-3-(methoxycarbonyl)pyrazine 1-oxide is utilized as a key building block in medicinal chemistry for its wide range of potential applications in the pharmaceutical industry. Its unique structure allows for the development of new drugs with diverse therapeutic profiles.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Amino-3-(methoxycarbonyl)pyrazine 1-oxide serves as an important intermediate, facilitating the creation of complex organic molecules for various applications.
Used in Cancer Treatment Research:
2-Amino-3-(methoxycarbonyl)pyrazine 1-oxide is explored as a potential anti-cancer agent, with studies focusing on its ability to inhibit the growth and proliferation of cancer cells. Its potential to target specific pathways involved in cancer development makes it a promising candidate for further research and drug development.
Used in Enzyme Inhibition Studies:
2-aMino-3-(Methoxycarbonyl)pyrazine 1-oxide has been investigated for its capacity to inhibit certain enzymes, which could be beneficial in treating specific diseases or conditions by modulating enzymatic activity.
Used in Drug Development for Cardiovascular and Neurological Disorders:
2-Amino-3-(methoxycarbonyl)pyrazine 1-oxide is also being studied for its potential role in developing new drugs to treat cardiovascular and neurological disorders, given its demonstrated biological activities that could be harnessed for therapeutic purposes in these areas.
Check Digit Verification of cas no
The CAS Registry Mumber 17149-35-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,1,4 and 9 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 17149-35:
(7*1)+(6*7)+(5*1)+(4*4)+(3*9)+(2*3)+(1*5)=108
108 % 10 = 8
So 17149-35-8 is a valid CAS Registry Number.
17149-35-8Relevant academic research and scientific papers
MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
-
Paragraph 00204, (2020/12/11)
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
Discovering a new class of antifungal agents that selectively inhibits microbial carbonic anhydrases
Annunziato, Giannamaria,Giovati, Laura,Angeli, Andrea,Pavone, Marialaura,Del Prete, Sonia,Pieroni, Marco,Capasso, Clemente,Bruno, Agostino,Conti, Stefania,Magliani, Walter,Supuran, Claudiu T.,Costantino, Gabriele
, p. 1537 - 1544 (2018/10/15)
Infections caused by pathogens resistant to the available antimicrobial treatments represent nowadays a threat to global public health. Recently, it has been demonstrated that carbonic anhydrases (CAs) are essential for the growth of many pathogens and their inhibition leads to growth defects. Principal drawbacks in using CA inhibitors (CAIs) as antimicrobial agents are the side effects due to the lack of selectivity toward human CA isoforms. Herein we report a new class of CAIs, which preferentially interacts with microbial CA active sites over the human ones. The mechanism of action of these inhibitors was investigated against an important fungal pathogen, Cryptococcus neoformans, revealing that they are also able to inhibit CA in microbial cells growing in vitro. At our best knowledge, this is the first report on newly designed synthetic compounds selectively targeting β-CAs and provides a proof of concept of microbial CAs suitability as an antimicrobial drug target.
